"Torlak" signed a contract for the production of Sputnik

Pridružite se poslovnoj zajednici od 20000 najuspešnijih i čitajte nas prvi

    “Torlak” signed a contract for the production of Sputnik

    The “Torlak” Institute has signed an agreement on technology transfer with the Russian Direct Investment Fund and the Russian pharmaceutical company Generium on procedures and technologies necessary for the production of the Russian vaccine “Sputnik V” in Serbia.

    This was announced by the Minister and President of the Intergovernmental Committee for Cooperation with Russia, Nenad Popovic.

    “As of this moment, “Torlak” has been exposed to data related to the production of the “Sputnik V” vaccine, developed by the most renowned Russian Research Institute of Epidemiology and Microbiology “Gamaleya”. It is sensitive and confidential data that can only be exchanged by partners who have great mutual trust,” said Nenad Popovic.

    He announced that three validation series of the “Sputnik V” vaccine will be produced at the Torlak Institute in April, and samples from these series will be sent for quality control to the Gamaleya Institute in Moscow.

    After the Russian institute confirms the validity of the samples, “Torlak” will start with the production of vaccine. We expect that to happen by May 20th this year, Popovic explained and pointed out that Serbia would thus become the first country in Europe to produce the “Sputnik V” vaccine.

    Izvor: RTS

    Foto: BIZLife

    What's your reaction?

    Ostavite komentar

    Vaša adresa e-pošte neće biti objavljena. Neophodna polja su označena *

    developed by Premium Factory. | Copyright © 2020 bizlife.rs | Sva prava zadržana.